Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13GlobeNewsWire • 01/09/23
Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid LeukemiaGlobeNewsWire • 12/22/22
Here's Why Affimed N.V. (AFMD) is Poised for a Turnaround After Losing 47.1% in 4 WeeksZacks Investment Research • 12/16/22
Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH 2022 MGlobeNewsWire • 12/12/22
Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell LymphomaGlobeNewsWire • 12/10/22
Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual MeetingGlobeNewsWire • 12/10/22
Affimed to Host Investor Event Highlighting AFM13 Clinical Development at 2022 ASH Annual MeetingGlobeNewsWire • 12/01/22
Affimed Reports Third Quarter 2022 Financial Results and Highlights Recent Clinical and Corporate ProgressGlobeNewsWire • 11/15/22
Affimed Provides Data Update from Two Phase 1/2a Trials with its Innate Cell Engager AFM24 in Solid Tumor Patients at the 37th SITC Annual MeetingGlobeNewsWire • 11/07/22
Affimed to Report Third Quarter 2022 Financial Results & Corporate Update on November 15, 2022GlobeNewsWire • 11/04/22
Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE®) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101GlobeNewsWire • 11/03/22
Affimed Announces Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells and Preclinical AFM28 Data at ASH 2022 Annual MeetingGlobeNewsWire • 11/03/22
Analysts Estimate Affimed N.V. (AFMD) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 11/02/22
Affimed Announces Two Clinical Update Presentations on its Novel Bispecific Innate Cell Engager AFM24 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)GlobeNewsWire • 10/05/22
Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (ESMO) Congress 2022GlobeNewsWire • 09/04/22